President Trump and U.S. Commerce Secretary Howard Lutnick have suggested imposing tariffs on imported pharmaceuticals, citing national security and the need for U.S. self-reliance in medicine manufacturing. While enhancing domestic production could be beneficial, the immediate effect of these tariffs is likely to increase costs for patients and result in drug shortages, echoing the situation in post-Brexit Britain. Most generic drugs are produced abroad, meaning tariffs could disrupt access to essential medications unless the U.S. drastically improves its local production capabilities.
One can't simply will the infrastructure and supply chains for the production of large amounts of medicines into existence overnight.
The U.S. has a good base for manufacturing branded medicines, but generic drugs are overwhelmingly produced overseas.
Collection
[
|
...
]